Biocon's shares saw a 1.66% increase, reaching ₹364.45, after the company announced that Health Canada has granted a notice of compliance (NOC) for its denosumab biosimilars, Bosaya and Vezuo. This approval signifies a critical step for Biocon in broadening access to affordable treatments for osteoporosis and cancer-related bone conditions. The decision was based on a robust set of analytical, nonclinical, and clinical data, confirming that Bosaya and Vezuo are highly similar to their reference products, Prolia and Xgeva, with no significant differences in quality, safety, or efficacy. Shreehas Tambe, CEO and managing director of Biocon, emphasized that this milestone reflects the company's strong scientific and regulatory capabilities. In its recent financial results, Biocon reported a consolidated net profit of ₹143.80 crore for the quarter ending December 2025, a substantial increase from ₹25.10 crore in the same quarter the previous year, with sales rising by 9.28% to ₹4,123 crore.